[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
January 2003

Sentinel Lymph Node Biopsy and Adjuvant Therapy for Melanoma: Evidence Revisited

Author Affiliations

Not Available

Arch Dermatol. 2003;139(1):99-100. doi:10.1001/archderm.139.1.99-a

In the September 2001 issue of the ARCHIVES, an Evidence-Based Dermatology Research Commentary took a dim view of sentinel lymph node (SLN) biopsy for melanoma, and discounted any potential benefit for adjuvant therapy.1 It is curious that this comment did not mention the preceding article by Dubois et al,2 in which a multidisciplinary panel of dermatologists, surgical oncologists, and medical oncologists provided guidelines for SLN biopsy and adjuvant therapy in patients with melanoma. Clearly, the consensus panel and the authors of the commentary have vastly different interpretations of the available evidence.

×